| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / NEW YORK, NY / ACCESSWIRE / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript |
Nyxoah SA (NASDAQ:NYXH ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Pearson Dennis - Investor Relations Olivier Taelman - Chief Executive Officer John Landry - Chief Financial Officer Conference Call Participants Jon Block - Stifel Adam Maeder - Piper Sandler Ross Osborn - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Michael Polark - Wolfe Research Laura Roba - Degroof Petercam Operator Good day and thank you for standing by. Welcome to the Nyxoah First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-14 18:35:21 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates |
Nyxoah SA (NYXH) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.45 per share a year ago. |
zacks.com |
2025-05-14 12:35:37 |
Czytaj oryginał (ang.) |
| Nyxoah Reports First Quarter Financial and Operating Results |
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Received an FDA Approvable Letter indicating the FDA will approve the Company's PMA application for its Genio® system subject to satisfactory completion of a manufacturing facilities, methods and controls review Successfully completed FDA validation requirements, final site inspection in progress at the U.S. contract manufacturing site Revenue for the first quarter of 2025 was €1.1 million, compared to €1.2 million in the first quarter of 2024 Launched Genio® 2.1 patient software upgrade in international commercial markets Cash, cash equivalents and financial assets were €63.0 million at March 31, 2025, compared to €85.6 million at the end of 2024 "We are excited that we are in the final stage of the FDA review process of our Genio® system in the United States," commented Olivier Taelman, Nyxoah's Chief Executive Officer. |
globenewswire.com |
2025-05-14 05:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-13 17:35:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). |
prnewswire.com |
2025-05-12 21:46:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. FMR LLC On May 2, 2025, Nyxoah received a transparency notification from FMR LLC. |
globenewswire.com |
2025-05-09 20:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 13:57:00 |
Czytaj oryginał (ang.) |
| Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025 |
REGULATED INFORMATION May 9, 2025, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 11, 2025 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. |
globenewswire.com |
2025-05-09 05:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). |
prnewswire.com |
2025-05-06 20:13:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-05 18:08:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-03 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-02 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-05-01 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). |
accessnewswire.com |
2025-04-30 16:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-04-29 15:35:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH |
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). |
prnewswire.com |
2025-04-28 22:09:00 |
Czytaj oryginał (ang.) |
| Nyxoah: The Future Of OSA |
Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment, with FDA approval expected in Q1 2025 acting as a potential catalyst for shares. Nyxoah, founded by Robert Taub, is led by Olivier Taelman and focuses on the Genio implant, which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate, Nyxoah has sufficient cash reserves to last until 2026, with U.S. market entry expected to significantly boost revenue post-FDA approval. |
seekingalpha.com |
2024-12-30 06:01:41 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. |
globenewswire.com |
2024-12-20 18:30:00 |
Czytaj oryginał (ang.) |
| Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England |
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London |
globenewswire.com |
2024-12-13 04:05:00 |
Czytaj oryginał (ang.) |
| Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference |
Nyxoah to Participate in the Piper Sandler 36 th Annual Healthcare Conference |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 |
REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. |
globenewswire.com |
2024-11-19 03:00:00 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. |
globenewswire.com |
2024-11-18 18:30:00 |
Czytaj oryginał (ang.) |
| Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript |
Nyxoah S.A. (NASDAQ:NYXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and IR Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Adam Maeder - Piper Sandler Joe Federico - Stifel Suraj Kalia - Oppenheimer Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day. |
seekingalpha.com |
2024-11-08 20:46:48 |
Czytaj oryginał (ang.) |
| Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates |
Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.29 per share a year ago. |
zacks.com |
2024-11-06 22:21:08 |
Czytaj oryginał (ang.) |
| Nyxoah Appoints John Landry as Chief Financial Officer |
Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. |
globenewswire.com |
2024-11-04 18:45:00 |
Czytaj oryginał (ang.) |
| Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:06:25 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 23, 2024, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. |
globenewswire.com |
2024-10-25 20:30:00 |
Czytaj oryginał (ang.) |
| Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 |
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. |
globenewswire.com |
2024-10-22 20:30:00 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 15, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received three transparency notifications as detailed below. Jürgen Hambrecht On October 15, 2024, Nyxoah received a transparency notification from Jürgen Hambrecht and Jürgen Hambrecht's controlled undertaking JH Capital GmbH following an acquisition or disposal of voting securities or voting rights. |
globenewswire.com |
2024-10-15 20:30:00 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 9, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On October 7, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons following a change to BlackRock's group structure. |
globenewswire.com |
2024-10-09 20:30:00 |
Czytaj oryginał (ang.) |
| Nyxoah Raises $27 Million through its At-the-Market Offering |
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company's $50 million at-the-market ("ATM") offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor. |
globenewswire.com |
2024-10-07 21:00:00 |
Czytaj oryginał (ang.) |
| DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update |
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline. 82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients who completed a polysomnography at 12 months had an AHI below 10. |
globenewswire.com |
2024-09-27 20:30:00 |
Czytaj oryginał (ang.) |
| Publication relating to transparency notifications |
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024 , 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons indicating that BlackRock Advisors, LLC went below the 3% threshold on September 20, 2024. |
globenewswire.com |
2024-09-27 06:00:00 |
Czytaj oryginał (ang.) |
| Nyxoah to Participate in Upcoming Investor Conferences |
Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver corporate updates at the Baird Global Healthcare Conference on Tuesday, September 10, 2024, at 12:15pm ET, the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 11:00am ET and the Cantor Global Healthcare Conference on Wednesday, September 18, 2024 at 1:55pm ET. |
globenewswire.com |
2024-09-05 20:30:00 |
Czytaj oryginał (ang.) |
| Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device |
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device |
globenewswire.com |
2024-09-02 20:05:00 |
Czytaj oryginał (ang.) |
| Nyxoah S.A. (NYXH) Q2 2024 Earnings Call Transcript |
Nyxoah S.A. (NASDAQ:NYXH ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Suraj Kalia - Oppenheimer Edward White - H.C. |
seekingalpha.com |
2024-08-11 05:44:09 |
Czytaj oryginał (ang.) |